Paying for Cell & Gene Therapy in the US: Is the Future Already Here?
Multiple novel payment models for CGT are currently deployed but an open and collaborative innovation approach among stakeholders is needed.
top of page
Vocal.
Search
Ulrich Neumann, MBA MSc MA
Apr 10, 20207 min read
New approaches to pharma sales: Success is marrying data analytics with the art of 1-1 engagement
In a world post-COVID, customer engagement matters more than ever before. Reflections on rethinking engagement in the field post pandemic.
Ulrich Neumann, MBA MSc MA
Apr 2, 20201 min read
Innovative Financing for Cell and Gene Therapies
The emergence of gene therapy and other transformative therapies has magnified concerns about affordability among payers, providers and...
Ulrich Neumann, MBA MSc MA
Apr 2, 20201 min read
Key Trends in US Specialty Pharmacy. Payer Perspectives and Developer Strategies, 2020-23
Payer perspectives and developer strategies for specialty drug coverage and utilization. Report, 33 pp.
Ulrich Neumann, MBA MSc MA
Apr 1, 20201 min read
AMCP Poster: A Systematic Comparison of Status Quo and Future Expectations for Novel Drug Financing
Journal of Managed Care and Specialty Pharmacy; April 2020 · Apr 1, 2020
Ulrich Neumann, MBA MSc MA
Apr 1, 20201 min read
AMCP Poster: A Survey-Based Analysis of Formulary Decision Making and Utilization Management Trends
Journal of Managed Care and Specialty Pharmacy; April 2020 · Apr 1, 2020
Ulrich Neumann, MBA MSc MA
Feb 29, 202013 min read
Netflix’s revenue model as a blueprint for pharmaceutical pricing?
An analysis of the economic and behavioral forces that led to the first adoption of subscription-based pricing for pharmaceuticals.
Ulrich Neumann, MBA MSc MA
Feb 21, 20201 min read
The Rise of Cost Effectiveness Considerations in the US.
Neumann U. (2020). The Rise of Cost Effectiveness Considerations in the US. Payer Views and Innovator Strategies. Certara.
Ulrich Neumann, MBA MSc MA
Feb 20, 20206 min read
Can we afford to pay for future cures?
Pharmaceutical R&D is racing ahead of our health system's ability to adjust payment models, but innovative concepts are finally emerging.
Ulrich Neumann, MBA MSc MA
Feb 7, 20201 min read
The Escalating US Policy Environment. Payer Views on Current Drug Pricing Proposals.
In recent years, health policy pushes have seen an increasing focus on drug costs. Proposals have embraced concepts like price...
Directly blog
bottom of page